UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

ShadowPatch: Shadow Based Segmentation for Reliable Depth Discontinuities in Photometric Stereo

Computer graphics forum, 2022-10, Vol.41 (7), p.635-646

2022

Volltextzugriff (PDF)

Invited Article: Bragg stacks with tailored disorder create brilliant whiteness

APL photonics, 2018-10, Vol.3 (10), p.100802-100802-6

2018

Volltextzugriff (PDF)

Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557

Antimicrobial Agents and Chemotherapy, 2009-11, Vol.53 (11), p.4885-4890

2009

Volltextzugriff (PDF)

Calafiore cardioplegia offers better myocardial protection in adult and senescent rat hearts than Del Nido cardioplegia

Perfusion, 2023-09, p.2676591231204290-2676591231204290

2023

Volltextzugriff (PDF)

Frequency of rpoB Mutations Inside and Outside the Cluster I Region in Rifampin-Resistant Clinical Mycobacterium tuberculosis Isolates

Journal of Clinical Microbiology, 2001-01, Vol.39 (1), p.107-110

2001

Volltextzugriff (PDF)

In Vitro Antifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries

Journal of chemotherapy (Florence), 2009-06, Vol.21 (3), p.272-281

2009

Volltextzugriff (PDF)

Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy

European journal of clinical microbiology & infectious diseases, 2000-07, Vol.19 (7), p.538-541

2000

Volltextzugriff (PDF)

Endotoxin-induced myocardial tumor necrosis factor-α synthesis depresses contractility of isolated rat hearts: Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production

Circulation (New York, N.Y.), 2000-11, Vol.102 (22), p.2758-2764

2000

Volltextzugriff (PDF)

Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment: Preliminary Experience

Journal of clinical gastroenterology, 2000-10, Vol.31 (3), p.222-225

2000

Volltextzugriff (PDF)

P987 Steady-state bioavailability of oral isavuconazole in healthy volunteers

International journal of antimicrobial agents, 2007, Vol.29, p.S262-S262

2007

Volltextzugriff (PDF)

Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2006-01, Vol.50 (1), p.279-285

2006

Volltextzugriff (PDF)

P1676 Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole-susceptible clinical Candida isolates

International journal of antimicrobial agents, 2007, Vol.29, p.S474-S475

2007

Volltextzugriff (PDF)

Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2006-01, Vol.50 (1), p.286-293

2006

Volltextzugriff (PDF)

P2027 Ceftobiprole activity and resistance patterns in staphylococcal isolates from a recent complicated skin and skin structure infection study

International journal of antimicrobial agents, 2007, Vol.29, p.S583-S584

2007

Volltextzugriff (PDF)

Daptomycin for the treatment of infective endocarditis: results from a European registry

Journal of antimicrobial chemotherapy, 2013-04, Vol.68 (4), p.936-942

2013

Volltextzugriff (PDF)

Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database

Journal of antimicrobial chemotherapy, 2013-07, Vol.68 (7), p.1642-1649

2013

Volltextzugriff (PDF)

P1950 In vivo efficacy of the triazole BAL8557 against disseminated Candida albicans in mice assessed by survival and tissue bur-den in temporarily and persistently neutropenic mice treated with 1 -7 doses of drug over a dose range of 20 -80%of Emax

International journal of antimicrobial agents, 2007, Vol.29, p.S560-S560

2007

Volltextzugriff (PDF)

P1675 QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole

International journal of antimicrobial agents, 2007, Vol.29, p.S474-S474

2007

Volltextzugriff (PDF)

Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole—an open pilot study

Alimentary pharmacology & therapeutics, 1998-12, Vol.12 (12), p.1273-1278

1998

Volltextzugriff (PDF)

Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany

Journal of antimicrobial chemotherapy, 2014-11, Vol.69 (11), p.3127-3133

2014

Volltextzugriff (PDF)

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus

Journal of antimicrobial chemotherapy, 2006-12, Vol.58 (6), p.1198-1207

2006

Volltextzugriff (PDF)

Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori

European journal of clinical microbiology & infectious diseases, 2002-02, Vol.21 (2), p.143-145

2002

Volltextzugriff (PDF)

Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

Antimicrobial agents and chemotherapy, 2000-04, Vol.44 (4), p.1075-1077

2000

Volltextzugriff (PDF)

Rifampin and rifabutin resistance mechanism in Helicobacter pylori

Antimicrobial agents and chemotherapy, 1999-06, Vol.43 (6), p.1497-1499

1999

Volltextzugriff (PDF)

Update on rifampin resistance in the Legionellaceae

Antimicrobial agents and chemotherapy, 2001-07, Vol.45 (7), p.2181-2182

2001

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(118)

Publikationsform

Artikel
(128)
Tagungsberichte
(7)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(91)
Life Sciences & Biomedicine
(67)
Humans
(64)
Biological And Medical Sciences
(41)
Female
(41)
Medical Sciences
(41)
Male
(40)
Adult
(22)
Technology
(21)
Middle Aged
(20)
Infant, Newborn
(19)
Aged
(17)
Microbiology
(16)
Pharmacology. Drug Treatments
(16)
Physics
(15)
Pharmacology & Pharmacy
(14)
Physical Sciences
(14)
Gastroenterology. Liver. Pancreas. Abdomen
(13)
Pediatrics
(13)
Prognosis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

ShadowPatch: Shadow Based Segmentation for Reliable Depth Discontinuities in Photometric Stereo

Invited Article: Bragg stacks with tailored disorder create brilliant whiteness

Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557

Calafiore cardioplegia offers better myocardial protection in adult and senescent rat hearts than Del Nido cardioplegia

Frequency of rpoB Mutations Inside and Outside the Cluster I Region in Rifampin-Resistant Clinical Mycobacterium tuberculosis Isolates

In Vitro Antifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries

Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy

Endotoxin-induced myocardial tumor necrosis factor-α synthesis depresses contractility of isolated rat hearts: Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production

Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment: Preliminary Experience

P987 Steady-state bioavailability of oral isavuconazole in healthy volunteers

Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

P1676 Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole-susceptible clinical Candida isolates

Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers

P2027 Ceftobiprole activity and resistance patterns in staphylococcal isolates from a recent complicated skin and skin structure infection study

Daptomycin for the treatment of infective endocarditis: results from a European registry

Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database

P1950 In vivo efficacy of the triazole BAL8557 against disseminated Candida albicans in mice assessed by survival and tissue bur-den in temporarily and persistently neutropenic mice treated with 1 -7 doses of drug over a dose range of 20 -80%of Emax

P1675 QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole

Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole—an open pilot study

Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus

Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori

Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

Rifampin and rifabutin resistance mechanism in Helicobacter pylori

Update on rifampin resistance in the Legionellaceae

Suchergebnisse filtern